Biohaven has concluded enrolment in the pivotal RISE3 Phase II/III trial assessing the selective Kv7.2/7.3 channel activator, ...
A new study found that later birth cohorts showed greater biological aging, measured by systemic age-gap clocks. Greater ...
"When it comes to getting a single new drug candidate to patients, research, regulatory approval, and market entry all ...
Cambrian Bio, a clinical-stage drug development company with pipeline therapies targeting critical metabolic pathways that ...
Dr Mom Hand, a United Kingdom-based developer of advanced botanical technologies with operations in the United States, Hungary and Turkey, today announced its proprietary Phyto~Resonance® extraction ...
Abstract: Brain-computer interfaces (BCIs) and their associated technologies have the potential to shape future forms of communication, control, and security. Specifically, the steady-state visual ...
See more of our coverage in your search results.Encuentra más de nuestra cobertura en los resultados de búsqueda. Add The New York Times on GoogleAgrega The New York Times en Google It’s never been ...
Forbion, a well-known backer of life sciences startups, is leading an investment round for a newly launched biotechnology company focused on diseases that affect nerve cells. The company, Progentos ...
Last Friday, Korro Bio announced the completion of the previously announced business combination between Frequency Therapeutics, Inc. and the entity formerly known as Korro Bio. The combined company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results